| Cas No.: | 903565-83-3 |
| Chemical Name: | (1S,3'R,4'S,5'S,6'R)-6-(4-ethylbenzyl)-6'-(hydroxymethyl)-3',4',5',6'-tetrahydro-3H-spiro[isobenzofuran-1,2'-pyran]-3',4',5'-triol |
| Synonyms: | CSG452; CSG-452; CSG 452; R-7201; R 7201; R7201; Tofogliflozin |
| SMILES: | CCC1=CC=C(C=C1)CC2=CC3[C@@]4(OCC=3C=C2)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4 |
| Formula: | C22H26O6 |
| M.Wt: | 386.444 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Tofogliflozin (CSG-452) is a potent, highly selective SGLT2 inhibitor with Ki of 2.9, 14.9, and 6.4 nM against human, rat, and mouse SGLT2, respectively; displays high selectivity over human SGLT2 versus human SGLT1, SGLT6, and sodium/myo-inositol transporter 1; increases renal glucose clearance and lowered the blood glucose level in Zucker diabetic fatty rats, also improves postprandial glucose excursion; reduces glycated hemoglobin and improved glucose tolerance in the oral glucose tolerance test in vivo.DiabetesApproved |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
